SparX Biotech(Jiangsu) Co.

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, SparX Biotech(Jiangsu) Co. sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

SparX Biotech(Jiangsu) Co.: 1 sponsored US clinical trial, 1 recruiting.

SparX Biotech(Jiangsu) Co. sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is RCC, with 1 trials.

Mid-pack sponsor footprint

SparX Biotech(Jiangsu) Co. is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING Phase 1

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

NCT06259552

Phase Distribution

PhaseTrial count
Phase 1 1

Therapeutic Areas

RCC 1
HNSCC 1
CRC 1
Solid Tumor 1

What is open in the SparX Biotech(Jiangsu) Co. pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: RCC (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

SparX Biotech(Jiangsu) Co.: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

SparX Biotech(Jiangsu) Co. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share SparX Biotech(Jiangsu) Co.1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
SparX Biotech(Jiangsu) Co. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

SparX Biotech(Jiangsu) Co. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this SparX Biotech(Jiangsu) Co. page

1 registered trials is a research-attention snapshot, not an endorsement of SparX Biotech(Jiangsu) Co. or any single study.

  • 1 of SparX Biotech(Jiangsu) Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • RCC is the condition SparX Biotech(Jiangsu) Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See RCC trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

SparX Biotech(Jiangsu) Co. pipeline card: 1 registered trials from official public datasets.Report a data error.